{"Clinical Trial ID": "NCT00880022", "Intervention": ["INTERVENTION 1:", "- Compression of arms only", "[Unspecified]", "INTERVENTION 2:", "Compression of the arm, face and chest", "[Unspecified]"], "Eligibility": ["Incorporation criteria:", "Persons at least six months after surgery and/or radiological treatment of breast cancer", "At least 21 years", "- Lymphedema in one arm after treatment of breast cancer with co-existing trunk swelling ** (first part) and *lymphedema in one arm after treatment of breast cancer without co-existing trunk swelling (second part)", "\u2022 Willingness and ability to drive to the study site if necessary", "Currently, do not use a compression pump or undergo manual lymphatic drainage by a therapist", "- Exclusion criteria:", "\u2022 Recipient active or less than six months after intravenous chemotherapy or radiation therapy", "People with congestive heart failure, chronic/acute renal failure, pulmonary cormon, nephrotic syndrome, nephrosis, hepatic failure or cirrhosis, pulmonary oedema, thrombophlebitis, deep venous thrombosis, infection of any kind and inflammation (redness) in the trunk or arms", "\u2022 History of bilateral breast cancer", "Metastatic cancer", "Inability to stand", "\u2022 Metal implants that interfere with bioimpedance measuring equipment", "Pregnancy", "\u2022 Vacuum cleaner and defibrillators implanted inside"], "Results": ["Performance measures:", "Volume of arms at the end of the study", "The volume per band was calculated and then by volume.", "Time frame: anticipated completion of treatment 30 days of treatment", "Results 1:", "Title of the arm/group: Compression of the arm only", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 21", "Median (interquartile range)", "Unit of measure: ml 2376.52 (1934.68 to 2622.99)", "Results 2:", "Title of the arm/group: Compression of the arm, chest and face", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 21", "Median (interquartile range)", "Unit of measurement: ml 2539.93 (2168.28 to 3295.97)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/21 (0.00 per cent)", "Adverse Events 2:", "Total: 0/21 (0.00 per cent)"]}